Large-Scale Intranasal COVID-19 Vaccine Clinical Trial to Come, Involving 10,000 Participants
The phase 2b study, which will begin in the fall of 2024, will evaluate the vaccine in a subset of participants at a higher risk of severe disease.University of Georgia-based startup CyanVac LLC received $40 million in federal funding on Wednesday to launch its intranasal COVID-19 vaccine clinical …
Read More